Galera Labs, LLC

Galera Therapeutics, LLC

Kereos, Inc.

Jeffery L Keene

Dennis Patrick Riley

Robert A Beardsley

Otto F Schall

Douglas R Spitz, Jr

Melissa Fath

A method of treating cancer in a subject includes administering at least one active agent including one or more of a thioredoxin reductase inhibitor and a glutathione depleting agent, and administering a pentaaza macrocyclic ring complex corresponding to formula (I) below:

Combination therapy for cancer treatment

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X.

Pentaaza macrocyclic ring complexes possessing oral bioavailability

The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.

Methods for treatment of diseases

A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor. 

Combination cancer immunotherapy with pentaaza macrocyclic ring complex

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula &#x2014;OC(O)X. 

The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect of the anti cancer agent(s).

Growing community of inventors

St. Louis, MO, United States of America

Jeffery L Keene